Intelligence Platform

Patents

Browse 376 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10745702

Compositions and methods for inhibiting expression of the LECT2 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10745704

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10709728

Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10683504

Serpina1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10683501

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventin

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10676740

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10668170

Modified RNAi agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10669544

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10669303

Compositions and methods directed to treating liver fibrosis

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10640770

Hepatitis D virus (HDV) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10612024

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10612027

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10597661

Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) an

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10570393

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10570391

RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) asso

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10557139

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10550390

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10550386

Monomers and oligonucleotides comprising cycloaddition adduct(s)

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10513703

Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10501740

Compositions and methods for inhibiting expression of factor V

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10501742

Compositions and methods for inhibiting expression of the PCSK9 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10494632

Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10478500

Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10472628

Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gen

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted